HER 2 LOW-EXPRESSING BREAST CANCER
Clinical trials for HER 2 LOW-EXPRESSING BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 LOW-EXPRESSING BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 LOW-EXPRESSING BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug switch strategy aims to outsmart tough breast cancer
Disease control Not yet recruitingThis study tests if switching between two different targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) can help people with a hard-to-treat, advanced breast cancer called HER2-low triple-negative breast cancer live longer. About 260 adults with metastatic or locall…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New scan method could spare breast cancer patients from unnecessary treatment
Knowledge-focused Not yet recruitingThis study looks at whether a special type of PET-CT scan can detect if a drug called trastuzumab deruxtecan is working earlier than standard CT scans in people with HER2 low breast cancer that has spread. About 262 participants will be followed to see if the scan helps doctors s…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC